Clinical

Dataset Information

0

A prospective, open, single-center, single-arm phase II clinical study of PD-1 inhibitor combined with Furquintinib or Regominib in the treatment of third-line and later advanced colorectal cancer patients

ABSTRACT: Interventions: Case series:PD-1 inhibitor combined with Furquintinib or Regominib Primary outcome(s): Effect and safety Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2698133 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
| S-EPMC7771363 | biostudies-literature
Unknown PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
| S-EPMC10944415 | biostudies-literature
Unknown Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study.
| S-EPMC9633934 | biostudies-literature
Unknown Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
| S-EPMC9801594 | biostudies-literature
Unknown An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.
| S-EPMC12411266 | biostudies-literature
Unknown The efficacy of regorafenib combined with PD-1/PD-L1 inhibitor in advanced or metastatic colorectal cancer: A single arm meta-analysis.
| S-EPMC12851704 | biostudies-literature
Clinical Phase II Clinical Trial for PD-1 inhibitor with Metronomic chemotherapy for Advanced Colorectal Cancer with microsatellite stability (MSS)
| 2692583 | ecrin-mdr-crc
Clinical A single center and single arm study for personalized neoantigen peptides vaccine in the treatment of advanced colorectal cancer
| 2683387 | ecrin-mdr-crc
Unknown Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure.
| S-EPMC10920016 | biostudies-literature
Unknown Pharmacokinetic and pharmacodynamic properties of ciprofol emulsion in Chinese subjects: a single center, open-label, single-arm dose-escalation phase 1 study.
| S-EPMC8748126 | biostudies-literature